Edition:
United States

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

0.69USD
14 Dec 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$0.69
Open
$0.73
Day's High
$0.74
Day's Low
$0.69
Volume
139,091
Avg. Vol
83,390
52-wk High
$2.55
52-wk Low
$0.69

Latest Key Developments (Source: Significant Developments)

DURECT Corporation Announces Q3 Loss Per Share $0.02
Wednesday, 7 Nov 2018 04:01pm EST 

Nov 7 (Reuters) - DURECT Corp ::ORATION ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 REVENUE $8.0 MILLION VERSUS I/B/E/S VIEW $8.6 MILLION.QTRLY LOSS PER SHARE $0.02.  Full Article

DURECT Says Co And Oxford Finance Entered Into Second Amendment To Loan And Security Agreement
Monday, 5 Nov 2018 09:30am EST 

Nov 5 (Reuters) - DURECT Corp ::DURECT CORP - ON NOVEMBER 1, CO AND OXFORD FINANCE ENTERED INTO A SECOND AMENDMENT TO ITS $20.0 MILLION LOAN AND SECURITY AGREEMENT.DURECT CORP - SECOND AMENDMENT MODIFIED TERMS OF LOAN AGREEMENT TO EXTEND FIRST PRINCIPAL PAYMENT DATE FROM DECEMBER 1, 2018 TO JUNE 1, 2020.  Full Article

Durect ADHD Capsules Receive Marketing Authorization In Taiwan
Tuesday, 18 Sep 2018 08:00am EDT 

Sept 18 (Reuters) - DURECT Corp ::DURECT ANNOUNCES METHYDUR SUSTAINED RELEASE CAPSULES RECEIVE MARKETING AUTHORIZATION FOR ADHD IN TAIWAN.DURECT - ORIENT PHARMA TOLD DURECT IT GOT MARKETING AUTHORIZATION FROM MINISTRY OF HEALTH & WELFARE IN TAIWAN FOR METHYDUR SUSTAINED RELEASE CAPSULES.DURECT CORP - ORIENT PHARMA ALSO STATED IT EXPECTS TO HAVE METHYDUR SUSTAINED RELEASE CAPSULES COMMERCIALLY AVAILABLE IN TAIWAN IN 2019.  Full Article

Durect Corp says U.S. FDA voted 14 to 3 against approval of Remoxy Er
Tuesday, 26 Jun 2018 08:30pm EDT 

June 26 (Reuters) - DURECT Corp ::RESULTS OF FDA ADVISORY COMMITTEE MEETING FOR REMOXY® ER.DURECT - U.S. FDA VOTED 14 TO 3 AGAINST APPROVAL OF REMOXY ER FOR MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE AROUND CLOCK, LONG-TERM OPIOID TREATMENT.PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR COMPLETION OF REVIEW IS AUGUST 7, 2018.DEVELOPMENT AND COMMERCIALIZATION RIGHTS OF REMOXY ER ARE HELD BY PAIN THERAPEUTICS (NASDAQ: PTIE) UNDER A LICENSE FROM DURECT.  Full Article

Durect Corporation Qtrly Earnings Per Share ‍$0.05​
Thursday, 1 Mar 2018 04:05pm EST 

March 1 (Reuters) - Durect Corp ::ORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND UPDATE OF PROGRAMS.Q4 REVENUE $19.5 MILLION.QTRLY ‍TOTAL REVENUES WERE $19.5 MILLION VERSUS $3.5 MILLION​.QTRLY EARNINGS PER SHARE ‍$0.05​.  Full Article

Durect reports Q3 earnings per share of ‍$0.04​
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Durect Corp :Durect Corporation announces third quarter 2017 financial results and provides corporate update.Q3 revenue $20.7 million.Q3 revenue view $3.7 million -- Thomson Reuters I/B/E/S.Quarterly earnings per share ‍$0.04​.  Full Article

Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint
Thursday, 19 Oct 2017 05:57pm EDT 

Oct 20 (Reuters) - Durect Corp :Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint.Durect Corp - ‍phase 3 clinical trial for Posimir(®) (saber(®)-bupivacaine), did not meet its primary efficacy endpoint​.Durect Corp - results from phase 3 clinical trial for Posimir​ trended in favor of Posimir versus comparator, but did not achieve statistical significance.  Full Article

Durect Q2 loss per share $0.07
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Durect Corp :Durect Corporation announces second quarter 2017 financial results and provides corporate update.Q2 revenue $4.3 million.Q2 revenue view $3.4 million -- Thomson Reuters I/B/E/S.Qtrly loss per share $0.07.Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Durect says ‍on July 24, Impax Laboratories terminated asset transfer and license agreement dated Jan. 3, 2014​
Friday, 28 Jul 2017 04:25pm EDT 

July 28 (Reuters) - Durect Corp :Durect - ‍on July 24, Impax Laboratories provided notice to co, that Impax is terminating asset transfer and license agreement dated January 3, 2014​.Durect Corp - termination returns to durect development and commercialization rights to Eladur(transdur)-bupivacaine) - SEC filing.  Full Article

Durect completes enrollment in persist, phase 3 trial for Posimir
Thursday, 22 Jun 2017 07:00am EDT 

June 22 (Reuters) - Durect Corp :Durect completes enrollment in Persist, phase 3 trial for Posimir.Durect - Durect remains responsible for completion of ongoing persist phase 3 clinical trial for Posimir as well as FDA interactions through approval.Durect Corp - phase 3 trial for Posimir top-line data on track for Q4 2017.  Full Article